New social plan at Sanofi

Two weeks after announcing the creation of a new vaccine factory in France and 610 million euros of investment, during a visit by Emmanuel Macron to its site in Marcy-l’Etoile (Rhône), Sanofi has presented, Monday, June 29, his ” 2020 reorganization project ” It plans to cut 1,700 jobs in Europe, spread over three years, including ” 750 to 1,060 In France, where the group still has a quarter of its workforce, or 25,000 people. The last plan, still in progress, dates back to June 2019, and involved nearly 470 people in France and Germany.

→ READ. Paracetamol formula should return to France

The new mainly concerns support and commercial functions, but also R & D positions. If no closure is planned among the 18 French factories, tertiary sites are affected, such as the Paris head office and the Val campus -de-Bièvre. The Strasbourg research center, which has around sixty employees, is also threatened.

Voluntary departures

Departures planned in France will be “ exclusively based on volunteering “, says management. A system of early retirement paid by the company should also be put in place. By proposing very advantageous financial conditions, Sanofi will undoubtedly have no difficulty in finding candidates to leave. ” In previous plans, there were even sometimes more requests than deleted positions, as many people want to leave the group. Explains a manager.

But in the current context, the pharmaceutical giant’s announcement goes badly and the unions denounce “ layoffs that have no place », In the words of Florence Faure, the CFDT delegate. Drug sales were boosted by the health crisis and Sanofi maintained this year the payment of a dividend to its shareholders for a total amount of around 4 billion euros. Sanofi receives “Each year 110 to 120 million euros in research tax credit”, also underlines Thierry Bodin, the CGT delegate.

Group refocusing

These announcements were, however, expected. The group’s new chief executive, the British Paul Hudson, had announced in December, three months after his arrival, that he wanted to save two billion euros by 2022, notably with a disengagement in diabetes and the cardiovascular system for the benefit of l ‘oncology.

The objective is to refocus the Sanofi portfolio on around 100 drugs, three times less than today. The unions are also worried about the sale of the consumer health center, which notably manufactures Doliprane.


Before his time.. a positive outlook on vaccine Sanofi anti-Corona

There are currently no vaccines for the Prevention of the virus, which has infected more than 9 million people and killed hundreds of thousands in the world, depends only doctors on certain drugs that have proven useful in helping patients “these 19” on the recovery.

In the shadow of the global race frantically to reach a safe and effective vaccine, said Paul Hudson, CEO of”Sanofi” if “anyone not yet certain of victory” and the development of the plant.

Said about this competition: “there are companies moving faster, but let’s be clear: Speed No 3 cons”, is the experience of the vaccine on the infected with other diseases such as “SARS”, and the possibility not to have the vaccine effective, as well as that the quantities available may not be enough for everyone.

Chief executive officer, said the probability of the success of Sanofi’s “higher than any other”.

Chime these comments with the statements of the president of the medical company “GlaxoSmithKline” who said to”Reuters”, the “company aimed at quality before speed”.

“Sanofi”, which enjoy the Department of vaccines by a good reputation especially in connection with the flu, working on two projects for the production of a vaccine against MERS-CoV, is scheduled to begin clinical trials of the vaccine developed by the with the “Galaxy Jiangsu” in September.


And stress good news in relation to the signing, where he guessed the two companies earlier, to have the vaccine available in the second half, not the first, of 2021.

She said, “Sanofi” she has the capacity to produce up to one million doses per annum of vaccines listed, and will be capable of supplying up to 360 million doses per annum.

Said John Reid, director of research at “Sanofi” when reporters asked about the time frame for the summary: “we use a dialogue with the regulatory authorities”.

There are currently no vaccines for the Prevention of the virus, which has infected more than 9 million people and killed hundreds of thousands in the world, depends only doctors on certain drugs that have proven useful in helping patients “these 19” on the recovery.

In the shadow of the global race frantically to reach a safe and effective vaccine, said Paul Hudson, CEO of”Sanofi” if “anyone not yet certain of victory” and the development of the plant.

Said about this competition: “there are companies moving faster, but let’s be clear: Speed No 3 cons”, is the experience of the vaccine on the infected with other diseases such as “SARS”, and the possibility not to have the vaccine effective, as well as that the quantities available may not be enough for everyone.

Chief executive officer, said the probability of the success of Sanofi’s “higher than any other”.

Chime these comments with the statements of the president of the medical company “GlaxoSmithKline” who said to”Reuters”, the “company aimed at quality before speed”.

“Sanofi”, which enjoy the Department of vaccines by a good reputation especially in connection with the flu, working on two projects for the production of a vaccine against MERS-CoV, is scheduled to begin clinical trials of the vaccine developed by the with the “Galaxy Jiangsu” in September.


Covid-19 vaccine. Europe must be “as efficient” as the United States,

French pharmaceutical giant Sanofi will not distribute a possible Covid-19 vaccine in the United States if the European Union proves to be “As effective” to finance its development, said its French official on Thursday. This is what the president of Sanofi France, Olivier Bogillot, said on the channel BFMTV.

Sanofi had warned the day before, through its managing director Paul Hudson, that it would give priority to the United States of a possible vaccine, because the American authorities have invested financially to support the research of the pharmaceutical giant.

He said the advance could be a few days or weeks. Such a possibility was judged on Thursday “Unacceptable” by Secretary of State for the Economy, Agnès Pannier-Runacher, who said that she immediately contacted Sanofi.

Treatment “accessible to all”

Asked repeatedly about a gap between the United States and the European Union (EU) in the distribution of a vaccine, the boss of Sanofi in France refrained from a clear denial, nevertheless ensuring that such treatment would be in fine ” accessible to everyone “.

“The goal is for the vaccine to be available both in the US, France and Europe in the same way”, he assured. But, in reality, it will be possible “If Europeans work as fast as Americans”, said Olivier Bogillot.

Gold, “The US government mobilized itself very early on financially”, he said, noting that the US had already planned to pay “Several hundred million euros”.

In contrast, “We are in talks with the European authorities […] and some EU states like France and Germany to speed things up “he continued, noting that it was also about facilitating regulatory procedures.

Regarding the research itself, Olivier Bogillot confirmed that the objective remained the development of a usable vaccine within 18 to 24 months, stressing that such a calendar is extremely accelerated compared to normal, which revolves around ‘ten years.


Disastrous economic data weigh on the Dax

Frankfurt The series historically poor economic datathat investors currently have to digest does not stop. That is also a burden for the German Leading index Dax. The stock market barometer closed on Friday 1.7 percent lower at 10,336 points.

“This drug had recently made a significant leap on the stock markets,” said Thomas Altmann, portfolio manager at QC Partners. “Therefore, this announcement is a clear warning to all euphoric investors.”

The puzzle is only slowly completing, how badly the corona pandemic is paralyzing the global economy. It was announced on Friday that the UK retail collapsed by more than four percent in March compared to the same period in the previous year – a decline that was not achieved even in the 2008 financial crisis.

Also in Japan the retail sector is idle: Merchants in the capital city of Tokyo reported a drop in sales of almost 35 percent in March. A similar decline to this extent is not to be found in the Bloomberg financial services time series.

There were also bad numbers from industry on Friday: The European commercial vehicle market fell almost half in March due to the coronavirus pandemic. With 105,196 vehicles, 47.3 percent fewer were registered than in the same month last year, the responsible industry association Acea announced on Friday in Brussels.

The number of registrations had already declined in January and February, but the decline in March was again considerably greater. The falls were most pronounced in the countries particularly hard hit by the Covid 19 pandemic: Italy (minus 66.1 percent), Spain (minus 64.4 percent) and France (minus 63.1 percent).

The managers surveyed by the Ifo Institute also assessed their situation as worse and are also more skeptical about the future. The published on Friday Ifo business climate index for April fell more clearly than expected: from 85.9 points in March to 74.3 points. That’s the lowest value ever measured. Economists interviewed by the Reuters news agency had expected a drop to 80.0 points. “The mood among German companies is catastrophic,” said Ifo President Clemens Fuest.

On Thursday, the GfK consumption barometer in Germany and the purchasing manager indices for the European service sector signaled that Germany and Europe were heading for a severe recession. The European Union is steering because of the corona crisis, according to EU Industry Commissioner Thierry Breton towards a drop in economic output of five to ten percent.

In addition, investors are also looking at the Federal Chancellor. Angela Merkel consults with representatives of business and trade unions on the corona crisis. This could also involve possible further easing and economic policy measures.

Look at the individual values

Deutsche Bank and Commerzbank: The rating agency Standard & Poor’s (S&P) has given it a thumbs-up because of the economic impact of the corona crisis at Commerzbank, Deutsche Bank and other German financial institutions. In the Commerzbank S&P downgraded the credit rating by one grade to “BBB +”, the outlook remains “negative”, as the credit rating officers announced on Thursday.

At Deutsche Bank, S&P confirmed the rating of the creditworthiness with “BBB +”, but lowered the outlook to “negative” from “stable”. While the creditworthiness guards doubt that Commerzbank can implement its new strategy “Commerzbank 5.0”, including the planned sale of the Polish subsidiary M-Bank, as planned, they see the restructuring of Deutsche Bank basically on track. The shares of the two largest German financial institutions fell by 6.8 percent (Deutsche Bank) and 4.1 percent (Commerzbank) and were among the biggest losers on the stock market on Friday.

Lufthansa: Down eight percent it went for the papers from Germany’s largest airline. So that leads Lufthansa the Dax’s list of losers. At € 7.20, the shares cost less than they had since the Sars pandemic 17 years ago. According to insiders, the airline plans to put together a government aid package of up to ten billion euros early next week. The loss increased to EUR 1.2 billion in the first quarter. Due to the pandemic, air traffic in Germany is almost completely stopped.

Nestlé: The Swiss food giant, on the other hand, is doing very well. Nestle accelerated its growth in the starting quarter 2020. Organic sales growth in the first three months was 4.3 percent, as Nestle announced on Friday. The share rose 1.8 percent. As the full impact of the Covid 19 pandemic could not yet be assessed, Nestle is tentatively sticking to the original outlook for 2020 as a whole. The Group expects organic sales growth and the underlying operating profit margin to improve.

Sanofi: The French pharmaceutical company benefits from the strong demand for painkillers and antipyretic due to the spread of the coronavirus. In the first quarter, currency-adjusted profit rose by 16.1 percent to 2.04 billion euros Sanofi announced. Sales climbed 6.6 percent to EUR 8.97 billion. Around half of the profit and sales growth is due to the corona pandemic. The corona effect will subside in the course of the second quarter. Sanofi confirmed the forecast for 2020. The group has set itself a five percent increase in earnings per share. The papers climbed 1.9 percent.

Eni: The Italian oil company the corona pandemic and collapsing oil prices drove a billion dollar loss in the first quarter. The net loss was 2.9 billion euros, as the Italian company announced on Friday in Rome. Had in the previous year Eni earned just under 1.1 billion euros. For example, Eni had to adjust the book value of its oil inventories to falling market prices, as well as depreciation on oil and gas activities. Adjusted, Eni achieved a small plus of 59 million euros, a fraction of the previous year’s profit of 992 million euros. Revenues plummeted by a quarter to around 13.9 billion euros. The stock lost 2.9 percent.

Look at other asset classes

Oil prices continued their recovery from the previous day on Friday despite the price losses in the meantime. The decisive factor on Wednesday, however, was not the easing of weakness in demand and excess supply, rather political tensions between the USA and Iran caused rising risk premiums for crude oil. In Asian trade, a barrel (159 liters) of the North Sea type Brent last cost $ 21.57, up 1.1 percent. The US WTI was traded at $ 17.09 per barrel, up 3.5 percent.

The euro exchange rate rose slightly on Friday. The European common currency was trading at $ 1.0804 in the late afternoon. The European Central Bank (ECB) set the reference rate on Friday at $ 1.0800 (Thursday: 1.0772).

Italy’s central bank Market insiders broadened their purchases of domestic government bonds on behalf of the ECB on Friday. The Banca d’Italia is buying slightly more titles on average than in the past few days, said a primary trader. A second insider said that she was more active on the market. Yields on ten-year bonds fell around ten basis points over the course of the day to 1.899 percent. They had previously climbed above the two percent mark when disappointment over the results of the EU summit on Thursday spread on the bond market.

With agency material.

Here is the page with the DAX course, here is the current tops & flops in the Dax. Current Short sales of investors can be found in our Short sales database.

“When planning wealth, the rule is: never get out completely!”


Investment experts were too euphoric

Frankfurt At the end of the week, many investors have regained their courage after there have been some hopeful reports in the fight against the corona virus.

Even if a drug to treat Covid-19 was found quickly, the way back to normality would be a long and rocky one, said portfolio manager Thomas Altmann from the investment advisor QC Partners. “The consequences of the economic lockdown at company level and the rise in the unemployment rate cannot simply be reversed.”

Timo Emden from the analytical company of the same name said something similar. “Investors are longing for the big hit in the corona pandemic,” he said. For the market, however, it is still clear that even an active ingredient is not a panacea for the affected global economy.

The German Leading index Dax climbed to 10,756 points on Friday. By the close of trading, however, he surrendered part of the profits and closed with a gain of almost 3.4 percent at 10,642 points. The development of the EuroStoxx 50 is similar: the European stock market index went out of trading with an increase of 2.7 percent at 2,888 points. In the US, investors were also initially in good spirits on Friday. The Dow Jones ended the year up 2.9 percent at 24,216 points.

Badly hit global economy

Jochen Stanzl, chief market analyst of the broker CMC Markets, compared the current increases in the stock market indices with the situation before the big sell-off in December and January. “Even now soaring technology stocks are driving like Netflix, Amazon and Tesla attention away from the fact that the real economy is in ruins, ”he said. “In the end, these companies will do good business, but they won’t save the global economy.”

Despite all the euphoria, the companies are “facing a major adjustment process, accelerated by the additional costs and burdens from the lockdown,” says Stanzl. At the moment, no one could say what the size of company closures would be in the end and how long it would keep stock exchanges from reaching the old highs.

In view of the relaxation of the contact restrictions, Jörg Krämer, chief economist at Commerzbankthat the economy will pick up strongly in the short term. “In the long term, however, there are considerable dangers – for example, due to the sharply increasing corporate debts caused by the crisis,” he said. A V-shaped upturn, i.e. a very rapid pickup in the economy, is unlikely. Rather, a gradual return to growth can be expected.

Jörg Krämer

The chief economist at Commerzbank expects the economy to pick up strongly in the short term.

In the coming week, the developments around the corona virus and current figures on the economic situation will continue to be the dominant topics on the markets. For example, stock marketers are eagerly awaiting the EU’s virus crisis summit next Thursday. Among other things, there will be a possible inclusion of jointly guaranteed debts to overcome the pandemic consequences.

In addition, shareholders will increasingly look at the quarterly figures of individual companies in the coming week. After companies in other countries have already submitted figures for the first quarter, the balance sheet season is now also beginning in Germany. The kick-off is as usual SAP.

In the current balance sheet season, a total slump in profits of 40 percent can be expected, said Ulrich Stephan, chief investment strategist for private and corporate customers at German bank. Nevertheless, he is optimistic: thanks to the multi-billion dollar aid packages from central banks and governments, investors are looking beyond current developments and are concentrating on profits in the second half of the year and 2021.

Entry into the stock market

Given the current price gains, some investors are wondering whether they have already missed the best opportunity to enter stocks. According to the DZ Bank analysts, the volatility will remain high for the time being due to the continuing uncertainties caused by the corona virus and further price setbacks cannot be ruled out. “From previous stock market cycles, we know that after a recession has bottomed out, the stock market has the highest and most sustained growth rates,” said DZ-Bank. “It will take some time before this low is reached. Our economists see this so far in the second quarter of 2020. “

Looking ahead to the coming years, the DZ Bank analysts expect: “By 2022/23, the Dax companies could earn as much again as in the previous record year 2018, and the Dax could reach its highest level again in 13,800 points in 2024.” Who in the continue to buy shares in the coming quarters, should achieve very good long-term investment results. However, it is important to only have shares in companies in the portfolio whose prospects are viewed positively over a three or five year period.

Altmaier wants to gradually ramp up the economy

This is how it will continue in the coming week:

Monday: At the beginning of the week, quarterly figures of Philips, Vivendi, and IBM expected. In Japan, figures on foreign trade are published in March, in Germany data on producer prices in March. The Bundesbank also publishes its monthly report.

Tuesday: The balance sheet season starts and SAP starts as usual. However, the software company had already published preliminary results in early April and lowered the full-year targets. In addition, Netflix, London Stock Exchange (LSE) and Coke Numbers before. The ZEW index provides information on the mood of German stock exchange professionals. UK unemployment figures come from London.

Wednesday: Preliminary data on consumer confidence in the euro zone are expected from Brussels. Lay at the company Alcoa, Ericsson, Caterpillar, Heineken and Roche first quarter figures.

Thursday: The publication of the GfK index will give an indication of the Germans’ buying mood. Alexander Roose, chief equity investor at asset manager Degroof Petercam, expects consumer confidence to “be severely impacted by the severe recession in the services sector due to rising health care costs and lower purchasing power”. In addition, the preliminary Markit purchasing manager index for the euro zone (industry, service, composite) is published. In the United States, the number of initial jobless claims for the week ending April 18 is published. Among other things, they provide insights into their books Credit Suisse, Volvo, Renault, Unilever and Intel.

Friday: At the end of the week, the Ifo index is on the schedule. It provides information about the mood on the German executive floors. Experts expect another slide to 77.2 points from 86.1 points in the previous month. In the United States, data on orders for durable US goods are also published. Experts expect a drop of 11.4 percent. Quarterly figures come from Sanofi, American Express and Nestle.

More: Yield in Corona times: With which investments you can still earn money


EU Research Commissioner stirs up hope for vaccine in autumn

Brussels, Frankfurt EU Research Commissioner Mariya Gabriel stokes hope that a coronavirus vaccine will be available quickly. Typically, the approval of a new serum takes twelve to 18 months, she told the Handelsblatt. “But we expect a vaccine to be available on the market much faster, possibly in the fall.” It was a race against time.

Companies and researchers are currently working on vaccines against the new Sars-CoV-2 coronavirus. Before being used, however, the active ingredients must be tested extensively for effectiveness and possible health risks. When it comes to safety, Gabriel should not make any compromises: “We cannot allow shortcuts in clinical trials that could endanger human life.”

The use of supercomputers can help to identify effective vaccines and medicines for the coronavirus more quickly, said the Bulgarian. An EU-funded research project called Exscalate4CoV uses the computers in Bologna, Barcelona and Jülich to identify molecules that may be effective against the virus. “What would take several years using conventional methods can be done by the supercomputers within a few months,” says Gabriel.

The Commission is funding 18 corona virus research projects with a total of 48.5 million euros from the EU funding program. The pan-European research teams are also working on faster detection tests for the virus.

Most experts and the responsible pharmaceutical authorities have so far been rather skeptical that a vaccine will be available before the end of the year. The background is not least the considerable difficulties that have been revealed in the past in many other vaccine projects, such as HIV or malaria.

Question of capacities

The European Medicines Agency (EMA) is also much more cautious. The timeline for new vaccine development is very difficult to predict, it said in its recent communication on the corona situation. It is estimated that it will take at least a year before a vaccine against Covid-19 is ready for approval and is available in sufficient quantities.

Overall, the agency says it is now holding talks about around a dozen development projects in this area. Two vaccine candidates are already in the first phase of clinical trials.

Virtually all established vaccine manufacturers like Glaxo-Smithkline, Pfizer or Sanofi are involved in development, as are a number of biotech companies. These include the German companies Curevac and Biontech. In cooperation with Pfizer, Biontech plans to start clinical trials for its own vaccine candidate at the end of April. Curevac plans this step in early summer. The US company Moderna has meanwhile brought a first candidate into clinical tests.

From there, there is still a long way to go before such a product is ready for the market. Because, like all vaccines, a Covid 19 vaccine will have to demonstrate a high level of safety in larger so-called phase III studies.

It is therefore not surprising that the WHO experts expected at least 18 months until a vaccine was available, explains Alexander Roussanov, partner at the Arnold & Porter law firm and former legal advisor for drug approvals at the EMA. In addition, the entire discussion cannot ignore whether there is sufficient capacity to start the production of the new vaccines quickly enough.

More: As an entrepreneur, I say: the contact blocks are correct. But if we don’t want to make trial and error decisions in the corona crisis, better data is essential.


Corona crisis: more independence in the health sector

Dhe Covid 19 pandemic is a historic and serious moment for Europe, a moment that shakes the foundations of the European project, be it the free movement of goods or people. The highest priority now is to contain the pandemic as quickly as possible and to protect the health of citizens. Once the pandemic is contained, we need to learn the lessons for our future in a “post-globalized” world. A key question should be: “Can the European Union and its Member States come together and become independent in the field of health?”

Since the onset of the crisis, Sanofi, the health company I head, has been doing everything possible to accelerate research into vaccines and drug treatments. And we are equally committed to maintaining the production and supply of medicines and vaccines for patients in Europe and the world, while protecting the health of our employees.

“We need more Europe”

The spread of the virus has clearly focused on issues that the EU Commission and the Member States should consider strategically important for dealing with future pandemics and health crises. These include crisis preparation, supply autonomy, as well as production capacity and industrial innovation.

Crisis preparation: Building on previous collaborations, Sanofi partnered with the United States Department of Health’s Biomedical Advanced Research and Development Authority (Barda) a month ago to develop a vaccine against Covid-19. Such a public-private partnership would not be possible in Europe as there is no agency responsible for responding to emerging health threats. The establishment of a European Barda agency could help the continent better deal with future health crises.

Paul Hudson, head of Sanofi pharmaceutical company

Autonomy of care: Covid-19 has aggravated the risk of excessive drug addiction dependency, which could jeopardize care in the event of a crisis. While not related to Covid-19, Sanofi’s recent announcement that it plans to create a leading pharmaceutical company (API) based in France by merging six of its European locations is relevant to the current situation. API are important molecules that are needed for the production of medicines. Our goal is to secure significant API manufacturing and delivery capabilities that are critical to patients in Europe and elsewhere. We need strong political support for such initiatives.

Production capacity and industrial innovation: There is tough global competition. The United States, China or Singapore are currently more attractive for industrial investments. We signed a financial agreement with Barda in December 2019 to increase our flu vaccine production capacity in the United States in the event of a pandemic. Covid-19 makes it clear that the EU member states invest in their production capacities and have to consider this as a question of independence.

However, while additional capacity could benefit all Member States if needed, the production facilities have to be located in one country. Therefore, for example, further exemptions from EU state aid rules could be considered, which allow Member States to support investments in state-of-the-art and digitized facilities. This would ultimately support the continent’s competitiveness at a global level and, more importantly, its ability to respond and innovate in times of crisis.

We need more Europe and a strong impetus from certain Member States. Because Europe’s best chance to compete and thrive in a post-globalized world lies in its ability to get the most out of its internal strengths. We have to keep this idea in mind when it is time to learn from the Covid 19 pandemic and build more resilient health systems. As a leading French, European and global company, we will be ready to do our part and work with companies in the sector, the EU institutions and the Member States to create Europe’s health independence.

Paul Hudson is the CEO of the French pharmaceutical company Sanofi.


Dax current: Dax fights with the 9000 point mark – Vapiano shares slide up to 70 percent

Investing in times of Corona: this is how investors should behave now

Dusseldorf Is the worst past the German stock market? The development on Friday could at least suggest that because the leading German index Dax lock 3.7 percent up at a As of 8928 points. In the meantime, the Frankfurt Stock Exchange Barometer even exceeded the 9200 point mark. With the papers from Fresenius, Heidelberg Cement, Allianz and Siemens, there were four papers with a double-digit percentage in the end. The Euro Stoxx 50 gained 3.9 percent to 2548 points.

Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks for free.


Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks for free.



The hunt for the corona vaccine

Laboratory samples

Researchers are working hard to find a vaccine against the coronavirus.

(Photo: Getty Images)

Düsseldorf, Frankfurt Prices continued to plummet on Monday’s global stock exchanges – but one company saw a huge price jump on Wall Street: The Mainz-based biotech company Biontech has made “rapid progress” in the development of a vaccine against the corona virus.

Biontech has been listed on the US stock exchange Nasdaq since autumn 2019, and the stock shot up 30 percent on Monday in New York. This is associated with the expectation that the German company will do good business with a corona vaccine – and that this product could be available in a few months.

Pharmaceutical and biotech companies around the world are working intensively on the development of an agent that will protect people from infections and the lung disease Covid-19. According to research by the Association of Researchers Pharmaceutical Companies (VFA), 40 vaccine projects against the new infectious disease are currently underway. When hunting for the Corona vaccine, the focus is on two German companies: Biontech and the Tübingen company Curevac.

Curevac belongs to the biotech holding company of SAP founder Dietmar Hopp and, like Biontech, is making progress in the search. “We should have a vaccine candidate against Corona at Curevac in early summer, which can then go into clinical development,” said Friedrich von Bohlen, Managing Director at Hopps holding company Dievini, the Handelsblatt.

What Trump wants from Curevac

The optimistic tones from Dietmar Hopp’s environment have also caused others to take notice – in recent weeks even the White House in Washington. In early March, US President Donald Trump invited leading representatives of pharmaceutical and biotech companies, all of whom are also involved in the development of vaccines. Curevac also belonged to the group of participants in Washington.

After the meeting, the Americans are said to have been even more interested in the Tübingen expertise and technologies. Trump is said to have lured the company with large sums of money – possibly with the aim of making a vaccine available, especially in the United States, according to media reports from the weekend. There was even talk of a purchase offer.

Bohlen underlines: “There was no offer to buy the company from the American side.” That was not correctly presented in some of the German media. What Trump’s government is generally interested in is the rapid availability of vaccines and therapeutic agents from a single source and in a process chain. This also applies to production capacities.


“When we invest in production systems that have not yet existed, we are talking about triple-digit millions,” says Bohlen. “Every company has to be open if investment interest is brought in.” At the same time, however, he underlines the conviction of Investor Hopp that applies to a corona vaccine and to all funds from the laboratories of its biotech companies: They should be available to people all over the world and the technologies for this should be established in Germany if possible.

“We would be happy if German and European politicians saw it that way and supported it financially,” says Bohlen. Innovation has its price, but above all it has great value.

Trump’s push has caused outrage in Berlin. The topic was on the agenda of the German government’s Corona Crisis Unit on Monday. She definitely wants to keep vaccine development in the country – also with financial help.

Bohlen does away with rumors that the change at the head of Curevac announced last week has to do with the process in the White House. “It’s more of a coincidence that we broke up by mutual agreement last week. Curevac has a strong team that is working flat out to develop the vaccine and its production capacity. ”

Like Biontech, Curevac is financially supported by the international vaccination initiative CEPI. China, the United States, several European countries, the Bill & Melinda Gates Foundation and the Wellcome Trust are involved in the global development program.